Cannabinoid-focused biopharmaceutical company C3 Pharmaceuticals, Inc. announced Wednesday that it has executed a tailored share subscription agreement with GEM Global Yield LLC SCS and is planning on listing on the Canadian Securities Exchange. The California company said it has a commitment of CAD$135 million ($99.3 million) from GGY. The money will expand manufacturing operations and introduceIdrasil,the company’s cannabis-based tablet, to the U.S. and international markets, according to C3. The tablet is aimed at helping patients manage a variety of conditions, such as chronic pain, ADD, A…
